GSK3B and schizophrenia: Kozlovsky et al. reported that both protein and mRNA of GSK-3β were decreased by approximately 40% in the postmortem frontal cortex of patients with schizophrenia relative to patients with bipolar or unipolar mood disorders and normal controls [129,130].